Dear Librarian

I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookseller, subscription agency, directly with the publisher or through a Karger representative.

The easiest way to order: www.karger.com/ddi

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com
International Journal of Gastroenterology

Founded as "Archiv für Verdauungskrankheiten" 1895 by I. Boas
Continued as "Gastroenterologia" 1939–1967

Editorial Board

A. Amanzada, Göttingen
W. Fischbach, Aschaffenburg
J. Gaedcke, Göttingen
G. Holtmann, Brisbane, Qld.
F. Itoh, Kawasaki
F. Kolligs, Berlin
F. Lordick, Leipzig
M.P. Lutz, Saarbrücken
H. Matsubara, Chiba
D. Müller, Marburg
M. Nakamura, Tokyo
A. Neesse, Göttingen
M. Pavel, Berlin
A. Perren, Bern
R.R. Plentz, Tübingen
J. Rosendahl, Leipzig
T. Seufferlein, Ulm
T. Sugai, Morioka
A. Weber, Munich
Guidelines for Authors

Submission
Digestion invites papers covering investigative physiology in humans and animals, metabolic studies, and clinical work on etiology, diagnosis, and therapy of human diseases. Original papers and reviews written in English are considered and should be submitted online at www.karger.com/dig

Authors may suggest up to five Referees who have expertise in the subject. Suggested Referees should not be from the same institution, not have published with the authors during the last 5 years, and should not be prejudiced. Should you experience problems with your submission, please contact S. Karger AG

Editorial Office "Digestion"
PO Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434
E-Mail dig@karger.com

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Digestion and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Authorship
Each author must have participated substantially in the work to take public responsibility for the content of the paper, and must give final approval of the final version of the manuscript.

Categories of Manuscripts
Original Papers are full-length research papers which will be published in the journal. Articles cover topics relevant to clinical and basic studies in the following areas: Physiology • Pathophysiology • Immunology • Cell Biology • Molecular Biology • Genetics • Nutrition • Epidemiology • Therapy.

Special Reviews are comprehensive, state-of-the-art reviews of important clinical problems. Reviews may be invited by the Editors or they may be unsolicited views. Abstract is required and should be divided into Background, Summary and Key Message. Reviews should consist of a maximum of 4,000 words.

Short Communications should not contain more than 2 printed pages (i.e. 5 manuscript pages), including an abstract, essential references and not more than 3 tables or figures. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts.

Meeting Reports are brief summaries of scientific meetings of gastrointestinal or liver topics. Authors should write a letter to the Editors inquiring about potential interest before submitting the paper.

Editorials provide comments on papers published in Digestion. Editorials are usually invited by the Editors.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define a case of plagiarism if there is 25% similarity in the text that exactly reproduces another paper without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the correspondent author should be provided. The key address may not be prejudiced. Should you experience problems with the submission, please contact S. Karger AG.

Color illustrations are reproduced free of charge. In the print version, the illustrations are reduced to technical reasons, figures with a screen background can be embedded in a document file but submitted separately (see detailed instructions on the Submission Website at www.karger.com/dig).

Color illustrations: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be included within the text at CHF 960.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 Mb in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.ﬁshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on
their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:
  "This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number]."

It is the author's responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author's behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's Choice™ (Gold Open Access) articles, see Author's Choice™.

**Author's Choice™**

Karger's Author's Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement:
  "The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number]."

It is the author's responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

**Funding Organizations (NIH etc.)**

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

**Page Charges**

There are no page charges for papers of 3 or fewer print-ed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 375.00. The allotted size of a paper is equal to approx. 10 manuscript pages (including tables, illustrations and references).

**Proofs**

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

**Reprints**

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Contents

See the journal website for contents
**JDDW 2017**

**FUKUOKA**

Japan Digestive Disease Week 2017

10/12 [THU.] – 15 [SUN.]

Fukuoka Kokusai Center
Fukuoka Sunpalace
Fukuoka International Congress Center
Marine Messe Fukuoka

---

**Participation/Registration Fee**

The Participation/registration fee is 15,000 JPY. (On-site registration only)

* You will be able to participate in JDDW 2017 without any additional fee, if you register JDDW 2017.

---

**Programs**

Please visit our website for details:

---

**Abstract Submission**

Online submission is available through the website above.
Submission period:
Wednesday, Feb. 1st – Wednesday, Mar. 22nd, 2017 at noon (Japan Standard Time)

---

**Contact Information**

Organization of JDDW
K-18 Bldg. 9F, 8-9-13 Ginza, Chuo-ku, Tokyo 104-0061 Japan
Tel: +81-3-3573-1254 E-mail: fukuoka2017en@jddw.jp
25th ueg week
advancing science, linking people

Barcelona, Spain
October 28 – November 1, 2017
Venue: Fira Gran Via

Professor Michael P. Manns MD, UEG President and Chairman of the Department of Gastroenterology, Hepatology and Endocrinology at the Hannover Medical School, Germany, looks forward to the 25th UEG Week Barcelona 2017.

UEG Week is now one of the world’s largest gastroenterology and hepatology meetings, attracting up to 13,000 participants from 114 countries. Leading scientists and clinicians come together to discuss the latest advances in our field, from new digestive health research to developments in clinical practice.

Every year, a world-class, innovative and interactive programme is carefully created by the UEG Scientific Committee and there are many highlights to look forward to in 2017. This includes the highly regarded ‘Today’s Science, Tomorrow’s Medicine’ lecture series, which will have a particular focus on Host Microbiota Crosstalk in 2017. This lecture series continues to implement the vital dialogue between basic scientists and clinicians and helps facilitate the development of novel therapies and technologies in clinical medicine.

We, at UEG, are very much looking forward to intensive days of scientific advances and updates from the world’s leading digestive health experts. One of my personal highlights are the UEG ‘Hotspot’ sessions, where attendees can expect intriguing and fascinating discussions and debates on the most exciting areas within our field. This includes the ‘Abstracts on FIRE’ series, where UEG Week’s leading abstracts are examined, explored and clinically reviewed by experts.

UEG is dedicated to providing young clinicians with a first-class congress experience and we are eager to deliver a platform to link people within the global GI community. The congress will deliver captivating post-graduate teaching sessions, providing attendees with state-of-the-art developments in gastroenterology and hepatology.

UEG Week is undoubtedly the best place for clinicians and scientists to present their research in gastroenterology and hepatology. As always, we look forward to rewarding the finest work in our field with a range of thoroughly-deserved awards. These include the UEG Research Prize, which honours an excellence in internationally-recognised research, and the Lifetime Achievement Award, which is awarded to an outstanding individual who has made fundamental contributions to digestive health that are widely acknowledged by the gastroenterological community. Awards are also given to the top abstracts and poster presentations that are submitted to the congress and UEG also honour between six and eight emerging clinical scientists with the UEG Rising Stars Awards.

With the first UEG Week taking place in Athens in 1992, this year marks the 25th anniversary for the congress. I, along with my fellow committee members, therefore welcome you to join us in celebrating this special 25th UEG Week in Barcelona.

*Abstracts previously presented at national or international meetings may be submitted providing that this is declared with submission

To find out more, visit www.ueg.eu/week
Cholangiocarcinoma

Editors
N.P. Malek
A. Königsrainer

Contents

Editorial
• Cholangiocarcinoma: Königsrainer, A.; Malek, N.P.

Review Articles
• Epidemiology and Risk Factors of Cholangiocarcinoma:
  Kirstein, M.M.; Vogel, A.
• Imaging of Cholangiocarcinoma: Olthof, S.-C.; Othman, A.;
  Clasen, S.; Schraml, C.; Nikolaou, K.; Bongers, M.
• Endoscopic and Photodynamic Therapy of Cholangiocarcinoma:
  Meier, B.; Caca, K.
• Locoregional Therapies of Cholangiocarcinoma: Sommer, C.M.;
  Kauzor, H.-U.; Pereira, P.L.
• Surgical Therapy of Cholangiocarcinoma: Radtke, A.;
  Königsrainer, A.
• Systemic Therapy of Cholangiocarcinoma: Plentz, R.R.; Malek, N.P.

Interdisciplinary Discussion
• Future Therapy of Cholangiocarcinoma: Plentz, R.R. (Chair)

Case Reports
• Small Bowel Obstruction due to a Giant Meckel's Diverticulum:
  Luu, A.M.; Meurer, K.; Herzog, T.; Uhl, W.; Tannapfel, A.; Braumann, C.
• Usefulness of Oblique Multiplanar Images on Multi-Detector
  Computed Tomography for Diagnosing Intersigmoid Hernia:
  Watanabe, T.; Yamamoto, Y.
Searching for the right journal to publish your latest findings?

East meets West – an integrative approach

Inflammatory Intestinal Diseases
Benfits of publishing in Inflammatory Intestinal Diseases
• Contribute to a new integrative approach
• Help improve the exchange of knowledge between East and West
• Currently no publication fee
• Rapid peer-review process
• Articles are published online within 4 weeks of acceptance and currently free access
• Possibility to integrate your ORCID identifier
• Track shares and engagements of your article with Altmetric

Please see the journal homepage for details: www.karger.com/iid

Editors-in-Chief
Gerhard Rogler, Zurich
Toshifumi Hibi, Tokyo
ISSN 2296–9403 (print)
e-ISSN 2296–9365 (online)

An international platform for key opinions and research

Gastro Intestinal Tumors
Benefits of publishing in Gastrointestinal Tumors
• Currently no publication fee
• Rapid peer-review process
• Articles are published online within 4 weeks of acceptance
• Possibility to integrate your ORCID identifier
• Track shares and engagements of your article with Altmetric
• Full text available in PubMed Central
• Included in the Thomson Reuters Emerging Sources Citation Index

Please see the journal homepage for details: www.karger.com/gat

Medical and Scientific Publishers

Editors
Jing-Yuan Fang, Shanghai
Peter Malfertheiner, Magdeburg
ISSN 2296–3774 (print)
e-ISSN 2296–3766 (online)
The Journal of Innate Immunity is a bimonthly journal covering all aspects within the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of ‘danger’, microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies. The journal publishes original research articles, short communications, reviews, commentaries and letters to the editors. In addition to regular papers, some issues feature a special section with a thematic focus.
To the Point Article

181 Cholangiocellular Carcinoma
Vogel, A.; Saborowski, A. (Hannover)

Editorial

186 Do Acid-Suppressing Medications in Inflammatory Bowel Disease Increase Risk for Flare?
Reinink, A.R. (Minneapolis, MN)

Original Papers

188 Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease
Shah, R.; Richardson, P.; Yu, H.; Kramer, J.; Hou, J.K. (Houston, TX)

194 Early-Stage Gastric Cancer Can Be Found in Improved Atrophic Mucosa over Time from Successful Helicobacter pylori Eradication

201 The Risk Factors for Metastasis in Non-Ampullary Duodenal Neuroendocrine Tumors Measuring 20 mm or Less in Diameter
Hatta, W.; Kosuke, T. (Sendai); Iijima, K. (Sendai/Akita); Asanuma, K.; Asano, N.; Musha, H.; Inomata, Y. (Sendai); Sano, T. (Kitakami); Endo, H. (Yamagata); Ikehata, A. (Morioka); Horii, T. (Obihiro); Ohyama, M. (Osaki); Yokosawa, S. (Ichinoseki); Kasajima, A.; Fujishima, F.; Sasano, H.; Nakaya, N.; Nakamura, T.; Shimosegawa, T. (Sendai)

210 Effects of Capsaicin on Older Patients with Oropharyngeal Dysphagia: A Double-Blind, Placebo-Controlled, Crossover Study

211 The Effect of Ineffective Esophageal Motility on Gastroesophageal Reflux Disease

229 Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels

237 Feasibility Study of the Three-Dimensional Flexible Endoscope in Endoscopic Submucosal Dissection: An ex vivo Animal Study

242 Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma